161 related articles for article (PubMed ID: 35705312)
1. Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.
Watson GA; Sanz-Garcia E; Zhang WJ; Liu ZA; Yang SC; Wang B; Liu S; Kubli S; Berman H; Pfister T; Genta S; Spreafico A; Hansen AR; Bedard PL; Lheureux S; Abdul Razak A; Cescon D; Butler MO; Xu W; Mak TW; Siu LL; Chen E
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705312
[TBL] [Abstract][Full Text] [Related]
2. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
6. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Bellmunt J; de Wit R; Fradet Y; Climent MA; Petrylak DP; Lee JL; Fong L; Necchi A; Sternberg CN; O'Donnell PH; Powles T; Plimack ER; Bajorin DF; Balar AV; Castellano D; Choueiri TK; Culine S; Gerritsen W; Gurney H; Quinn DI; Vuky J; Vogelzang NJ; Cristescu R; Lunceford J; Saadatpour A; Loboda A; Ma J; Rajasagi M; Godwin JL; Homet Moreno B; Grivas P
Clin Cancer Res; 2022 May; 28(10):2050-2060. PubMed ID: 35247908
[TBL] [Abstract][Full Text] [Related]
7. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
12. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
14. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; Filetti M; Pizzutilo P; Russano M; Citarella F; Cantini L; Targato G; Nigro O; Ferrara MG; Buti S; Scodes S; Landi L; Guaitoli G; Della Gravara L; Tabbò F; Ricciardi S; De Toma A; Friedlaender A; Petrelli F; Addeo A; Porzio G; Ficorella C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077515
[TBL] [Abstract][Full Text] [Related]
15. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.
Lo Russo G; Sgambelluri F; Prelaj A; Galli F; Manglaviti S; Bottiglieri A; Di Mauro RM; Ferrara R; Galli G; Signorelli D; De Toma A; Occhipinti M; Brambilla M; Rulli E; Triulzi T; Torelli T; Agnelli L; Brich S; Martinetti A; Dumitrascu AD; Torri V; Pruneri G; Fabbri A; de Braud F; Anichini A; Proto C; Ganzinelli M; Mortarini R; Garassino MC
ESMO Open; 2022 Dec; 7(6):100645. PubMed ID: 36455507
[TBL] [Abstract][Full Text] [Related]
16. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
17. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
Galsky MD; Saci A; Szabo PM; Han GC; Grossfeld G; Collette S; Siefker-Radtke A; Necchi A; Sharma P
Clin Cancer Res; 2020 Oct; 26(19):5120-5128. PubMed ID: 32532789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
